Opinion on Therapy Area in South and Central America

Published within

« | ... | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

GSK: renewing the HIV pipeline

GlaxoSmithKline and Idenix are to co-develop IDX899 for the treatment of HIV infection. Despite having eight marketed HIV products, GSK lost its position as market leader to Gilead in 2007. The new collaboration with Idenix will, however, help the company to maintain its share in the fiercely competitive HIV market.

Published By Datamonitor
09 Feb 2009
CommentWire
CommentWire

GSK: vaccine deal increases presence in emerging markets

Following several investments in Asia earlier this year, GlaxoSmithKline has further expanded its vaccines presence in the emerging markets through a deal with Brazil's Fiocruz. However, with competitors such as Wyeth and Sanofi Pasteur also aggressively expanding into these geographies, Datamonitor expects a fierce competition for market share.

Published By Datamonitor
18 Aug 2009
ResearchWire
ResearchWire

Heart failure: pipeline dominated by approved drugs

Published By Datamonitor
31 Aug 2007
ResearchWire
ResearchWire

Hematological malignancies: hunt for next blockbuster drives pipeline activity

Published By Datamonitor
16 May 2007
ResearchWire
ResearchWire

Hepatitis C: protease inhibitors to drive market expansion

Published By Datamonitor
21 Jul 2006
CommentWire
CommentWire

HIV drugs: patent disputes escalate

Published By Datamonitor
28 Aug 2001
Expert View
Expert View

HIV market: collaborative combinations

Two new HIV drugs, from Tibotec and Gilead, have been shown to be viable late-stage pipeline candidates. However, both TMC278 and elvitegravir are set to compete head-to-head against more widely-used competitors. In the longer term, both candidates could improve usage and penetration through use in collaborative combination therapies.

Published By Datamonitor
12 Mar 2007
CommentWire
CommentWire

HIV patents: no solution - yet

While the WTO has not yet made a breakthrough on the issue of patent-free HIV drugs for developing economies, something must be done to alleviate the human and economic cost of the HIV epidemic. Western pharma companies will inevitably lose out - the only question is how well their profit maintenance strategies can cushion the blow.

Published By Datamonitor
22 Oct 2002
CommentWire
CommentWire

HIV: US senate may face more pressure

Many patient advocacy groups argue that the US is not contributing sufficiently to HIV prevention and treatment, despite the recent budget approval. Furthermore, most of the major HIV drug manufacturers are either US based or heavily involved in the US - a factor likely to provide additional pressure for increased funding.

Published By Datamonitor
21 May 2003
Expert View
Expert View

Hope for an Alzheimer's breakthrough remains despite Dimebon's failure

A Phase III trial evaluating Medivation/Pfizer's Dimebon in Alzheimer's disease has failed to meet any of its clinical endpoints, despite high hopes of the drug after promising Phase II results. This is a significant setback for Dimebon's developers, particularly Medivation, but hope for the millions of Alzheimer's sufferers and their caregivers remains in the pipeline.

Published By Datamonitor
04 Mar 2010

« | ... | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | ... | » »|

No help is available.